10x Genomics, Inc. Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost
10x Genomics, Inc. (TXG) had Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost of $24.38 million as of 2025-12-31, per its 10-K filed 2026-02-13.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Tax Deferred Expense
us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost · last filed 2026-02-13
- 2025-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $24.38M.
- 2024-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $26.77M.
- 2023-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $24.34M.
- 2022-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $20.91M.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost |
|---|---|
| 2025-12-31 | $24.38M 10-K · filed 2026-02-13 |
| 2024-12-31 | $26.77M 10-K · filed 2026-02-13 |
| 2023-12-31 | $24.34M 10-K · filed 2025-02-13 |
| 2022-12-31 | $20.91M 10-K · filed 2024-02-15 |
| 2021-12-31 | $12.26M 10-K · filed 2023-02-16 |
| 2020-12-31 | $6.60M 10-K · filed 2022-02-18 |
| 2019-12-31 | $1.43M 10-K · filed 2021-02-26 |